Neurogene Inc. Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised
Neurogene Inc. (NGNE) reported Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised of $84.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-24.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans · last filed 2026-03-24
- Neurogene Inc. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for the quarter ending 2023-09-30 was $0.00.
- Neurogene Inc. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for the quarter ending 2022-12-31 was $19.00K, a 87.58% decline year-over-year.
- Neurogene Inc. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for the quarter ending 2022-09-30 was $0.00.
- Neurogene Inc. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for the quarter ending 2021-12-31 was $153.00K, a 23.12% decline year-over-year.
- Neurogene Inc. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for fiscal 2025 was $84.00K.
- Neurogene Inc. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for fiscal 2024 was $0.00.
- Neurogene Inc. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for fiscal 2022 was $82.00K, a 77.96% decline from fiscal 2021.
- Neurogene Inc. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for fiscal 2021 was $372.00K, a 86.93% increase from fiscal 2020.
| Period end | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised 3 month | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised 6 month | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised 9 month | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised 12 month |
|---|---|---|---|---|
| 2025-12-31 | $84.00K 10-K · filed 2026-03-24 | |||
| 2024-12-31 | $0.00 10-K · filed 2026-03-24 | |||
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $4.00K 10-Q · filed 2023-11-14 | ||
| 2023-06-30 | $4.00K 10-Q · filed 2023-08-10 | |||
| 2022-12-31 | $19.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-20 | $19.00K derived: sum of 2 quarters · filed 2023-11-14 | $82.00K 10-K · filed 2023-03-20 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $63.00K 10-Q · filed 2023-11-14 | ||
| 2022-06-30 | $63.00K 10-Q · filed 2023-08-10 | |||
| 2021-12-31 | $153.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-20 | $153.00K derived: sum of 2 quarters · filed 2023-03-20 | $372.00K 10-K · filed 2023-03-20 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $219.00K 10-Q · filed 2022-11-14 | ||
| 2021-06-30 | $219.00K 10-Q · filed 2022-08-09 | |||
| 2020-12-31 | $199.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $199.00K derived: sum of 2 quarters · filed 2022-03-01 | $199.00K 10-K · filed 2022-03-01 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $0.00 10-Q · filed 2021-11-04 | ||
| 2020-06-30 | $0.00 10-Q · filed 2021-08-05 | |||
| 2019-12-31 | $0.00 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |